NASDAQ:CHRN ChronoScale Corporation Common Stock Q1 2026 Earnings Results & Report $16.05 +1.17 (+7.86%) As of 04:00 PM Eastern ChronoScale Corporation Common Stock missed analyst expectations on both earnings and revenue in its Q1 2026 results, released April 28, 2026. The company reported EPS of -$2.04 versus the -$0.03 consensus estimate, while revenue of $2.14 million fell short of the $4.29 million estimate by $2.15 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateApril 28, 2026TimeBefore Market OpensConference Call8:00 AM ET ChronoScale Corporation Common Stock EPS ResultsActual EPS-$2.04Consensus EPS -$0.03Beat/MissMissed by -$2.01One Year Ago EPSN/AEPS Beat Rate1 of last 8 quartersChronoScale Corporation Common Stock Revenue ResultsActual Revenue$2.14 millionExpected Revenue$4.29 millionBeat/MissMissed by -$2.15 millionYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) ChronoScale Corporation Common Stock Q1 2026 Earnings FAQ Did ChronoScale Corporation Common Stock beat earnings estimates for Q1 2026? ChronoScale Corporation Common Stock (NASDAQ:CHRN) reported earnings of -$2.04 per share for Q1 2026, missing the consensus estimate of -$0.03. The report was announced on Tuesday, April 28, 2026. What was ChronoScale Corporation Common Stock's revenue for Q1 2026? ChronoScale Corporation Common Stock reported revenue of $2.14 million for Q1 2026, against a consensus estimate of $4.29 million. ChronoScale Corporation Common Stock Earnings HeadlinesChronoScale Reports Fiscal First Quarter 2027 Results2 hours ago | globenewswire.comChronoScale: Fiscal Q1 Earnings SnapshotOctober 14 at 11:50 PM | finance.yahoo.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.October 15 at 1:00 AM | Weiss Ratings (Ad)ChronoScale Corporation Common Stock (NASDAQ:CHRN) Stock Crosses Below Fifty Day Moving Average - Here's What HappenedOctober 10, 2026 | americanbankingnews.comFollowing a major business transformation, ChronoScale is doubling down on AI infrastructure betOctober 6, 2026 | msn.comChronoScale (NASDAQ: CHRN) lines up $1 billion run-rate after Ekso saleOctober 5, 2026 | americanbankingnews.comSee More ChronoScale Corporation Common Stock Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ChronoScale Corporation Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ChronoScale Corporation Common Stock and other key companies, straight to your email. Email Address About ChronoScale Corporation Common StockEkso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.View ChronoScale Corporation Common Stock ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
